Current clinical protocols used for isolation and purification of mesenchymal stem cells (MSC) 
Introduction

The ability of mesenchymal stem cells (MSC) to differentiate along multiple pathways, together with their relatively easy isolation from BM and their extensive capacity for in vitro expansion, makes MSC potentially the most attractive population among stem cells
for tissue engineering and cell therapy applicable on a variety of congenital and acquired diseases [1] [2] [3] . In addition to their role in regenerative therapies, MSC have been consistently shown to possess immunomodulatory properties, which may play a role in the maintenance of peripheral tolerance, the induction of transplantation-related tolerance and control autoimmunity [4, 5] . There are preliminary data supporting their clinical efficacy in controlling steroid resistant graft versus host disease (GVHD) and improving engraftment of donor cells in the allogeneic stem cell transplant setting. However, the beneficial role of MSC in GVHD prophylaxis is being questioned by small-scale randomized clinical trials [6, 7] .
Further large-scale randomized studies are needed to clarify the benefits and hazards of MSC administration for the prevention and therapy of GVHD.
In all clinical protocols, MSC have been isolated from bone marrow mononuclear cells (BM-MNC) and amplified in culture media supplemented with foetal calf serum [8, 9] , or human platelet lysate [10] . Such [11, 12] . Recent (Fig. 4) .
We 
